Fig. 1: Time to treatment failure (TTF) for ADC1 and ADC2 with or without intervening therapy (IntTx).

A–D Double-headed Swimmer Plots demonstrating time on treatment in months for each antibody drug conjugates (ADC). Patients with HR + /HER2-low MBC are shown at left (A, B) and those with HR-/HER2-low MBC are shown at right (C, D). Patients receiving sacituzumab govitecan (SG, red) followed by trastuzumab deruxtecan (T-DXd, blue) are shown in the top row (A, C) and patients receiving T-DXd followed by SG are in the bottom row (B, D). For each tornado plot, each bar represents an individual patient. The time on treatment for the first ADC (ADC1) is shown at left, if the patient received an intervening therapy (InTx) the time on treatment is shown in green in the middle (with different shades of green representing subsequent lines of intervening therapy; if no green bar then the patient did not receive an intervening therapy), and the time on treatment for the second ADC (ADC2) is shown at right. Patients stopped ADC therapy due to progression unless otherwise noted as due to toxicity (X) or if they were still on therapy at the time of data cutoff (>).